MarketsandMarkets

Real-World Evidence and Market Access Conference - EU Edition

5th - 6th October 2023

The Westin Grand Frankfurt, Germany

100+

Attendees

30+

Speakers

15+

Networking Hours

10+

Exhibitors

Revolutionizing Healthcare with RWD / RWE to Accelerate Regulatory Decision Making

Real-world data and real-world evidence are poised to keep making strides in 2023. This analysis of clinical evidence studies the usage, potential advantages and risk of a medical product inferred from the real-world data analysis. Real-world evidence (RWE) is accelerating its involvement in the early benefit elucidation of medicinal drugs.

RWE solutions have proven to be extremely useful, as they allow industrial and academic researchers to monitor patients using digitally connected platforms while assisting to organize and evaluate clinical data for regulatory submissions. Since RWE research is still in an evolution process, and few gaps in the area have been explored, more guidance and a consented annotation is obligatory to increase the effectuation of real-world data.

After five successful editions of Real-World Evidence and Life Sciences Analytics Conference in Boston, USA, MarketsandMarkets is proud to announce its upcoming Europe edition of Real-World Evidence and Market Access Conference to be held on October 5th- 6th 2023 at The Westin Grand Frankfurt, Germany. The conference will bring the full spectrum of experts, leaders, and stakeholders to share a board prospective on significant points and hold discussions on the best practices with a key takeaway being better decision making.

WHAT TO EXPECT

  • Regulatory view around data quality & data standards.
  • Leveraging RWE for improving market access.
  • The adoption & role of AI & ML in clinical trials.
  • Real-world evidence & Digital Health - The expanded role of RWE for digital health.
  • Real-World Data & Advanced Analytics.
  • RWE to inform decision making process in rare diseases where there is lack of evidence.

  • Learn about the recent trends and advancements in Real-World Evidence Generation 
  • Engage in meaningful discussion with the most prominent industry experts and decision makers from pharmaceutical and biopharmaceutical companies who will address most critical challenges in real-world data and real-world evidence space. 
  • Opportunity to network and exchange scientific knowledge with expert speakers from leading pharmaceutical companies, global regulators and solution providers

From Pharmaceutical and Biopharmaceutical companies

Chief executives, VP’s, Directors, Global heads, Heads, Leaders, Senior Managers, Researcher, Analysts, Investigators, Scientists within the following departments-

  • Real-World Evidence
  • Real-World Data
  • Data Analytics
  • Health Economics & Outcomes Research- HEOR
  • Market Access/Value Access
  • Policy
  • Clinical Development & research
  • Clinical trial
  • Centre for Observational and Real-World Evidence
  • Epidemiology
  • Oncology-RWE
  • Pricing and Reimbursement
  • Medical Affairs
  • Pharmacovigilance
  • Life Science Analytics
  • Big data
  • Data Science
  • Bio-Statistics
  • Consumer Healthcare

CONFERENCE AGENDA

Registration

08:15 - 08:50

Welcome note by MarketsandMarkets

08:50 - 08:55

Opening remarks by the Chairperson

Helene Vioix

Helene Vioix, Director Global Evidence & Value Development Oncology, Merck KGaA

08:55 - 09:00

Application of Real-World Evidence (RWE) in Medication and Outcomes

Patient Access to Precision Medicine Oncology

09:00 - 09:30

Maximizing the influence of RWD in cases of Rare Diseases

Helene Vioix

Helene Vioix, Director Global Evidence & Value Development Oncology, Merck KGaA

09:30 - 10:00

Solution Provider Presentation - Lynx Care

Dries Hens

Dries Hens, Chief Medical Officer, Co-founder , LynxCare

Shahbaz Pervaiz

Shahbaz Pervaiz, Director of RWE Services, LynxCare, Inc.

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meeting

10:30 - 11:20

Population Adjusted RCTs – An Option for HTA Authorities

Michael Happich

Michael Happich, Sr Director HTA, International Markets, Eli Lilly and Company

11:20 - 11:50

Accelerate and de-risk Clinical Development & Market Access through AI-powered Real- World Disease and Care simulation.

Alexandre Templier

Alexandre Templier, President, Quinten Health

11:50 - 12:20

RWE in Radiology: Promises and Pitfalls

Oisin Butler

Oisin Butler, Integrated Evidence Generation Lead, Bayer Radiology

12:20 - 12:50

Presentation by

Davy Yeung

Davy Yeung, Managing Director and Vice President of Operations, Tailored Clinical Research Solutions

12:50 - 13:20

Lunch and Poster Presentation | One-to-One Networking

13:20 - 14:20

Let the Data Flow – Automated Digital Data Transfer from EHRs to EDC

Christian Müller

Christian Müller, Head of Data Generation, Bayer

14:20 - 14:50

From Data to Dialogue: Elevating Science-Based Communication in Post-Approval Studies

Veronika Schweighart

Veronika Schweighart, Co-Founder, Climedo

14:50 - 15:20

Panel Discussion: Real-world Effectiveness- Does it Matter?’

Sandeep Kiri

Sandeep Kiri, UCB Global Payer Value Strategy- Head of Health Economics and HTA Evidence, UCB

Helene Vioix

Helene Vioix, Director Global Evidence & Value Development Oncology, Merck KGaA

Michael Happich

Michael Happich, Sr Director HTA, International Markets, Eli Lilly and Company

Christian Müller

Christian Müller, Head of Data Generation, Bayer

Ivan Clement

Ivan Clement, Global Associate Director, RWE & Innovative Evidence in Neuroscience , Novartis

15:20 - 15:50

Evening Refreshments and Poster Presentation | One-to-One Networking

15:50 - 16:30

Current Trends in Patient-Centric Clinical Research amid the Rapidly evolving Landscape

Meritxell Sabidó

Meritxell Sabidó, Director- Global Epidemiology Department, Neurology and Immunology, Merck Healthcare KgaA

16:30 - 17:00

Patient Engagement Strategy and Execution

17:00 - 17:30

Achieving Patient Diversity using RWE in Clinical Trials

17:30 - 18:00

Closing remarks by the Chairperson

Helene Vioix

Helene Vioix, Director Global Evidence & Value Development Oncology, Merck KGaA

18:00 - 18:00

End of Day 1

18:00 - 18:00

Registration

08:15 - 08:50

Welcome note by MarketsandMarkets

08:50 - 08:55

Opening remarks by the Chairperson

08:55 - 09:00

Role of Real-World Evidence (RWE) in Market Access – Approach and Planning

RWE- Trends in Global Market and Network Access

09:00 - 09:30

Patient Centricity in Health Technology Assessment

Remon Helmy

Remon Helmy, Senior Manager, Global Health Economics & Outcomes Research (HEOR), Alexion Pharmaceuticals

09:30 - 10:00

Solution Providers Presentation

Alberto Brage

Alberto Brage, Global Key Account Manager, Savanamed

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking

10:30 - 11:15

RWE in HTA- What does it mean in the ‘Real World’

Sandeep Kiri

Sandeep Kiri, UCB Global Payer Value Strategy- Head of Health Economics and HTA Evidence, UCB

11:15 - 11:45

The Socioeconomic Impact of Medical Innovation

Ahmed H. Seddik

Ahmed H. Seddik, Senior Manager, Global HEOR & RWE, Oncology, Daiichi Sankyo Europe GmbH

11:45 - 12:15

Panel Discussion - The Evolution of Registries and their Value for Patients’ Communities, Payers, and Regulators.

Anila Dede

Anila Dede, Executive Director -Medical Affairs, RW Solutions, SyneosHealth

Ahmed H. Seddik

Ahmed H. Seddik, Senior Manager, Global HEOR & RWE, Oncology, Daiichi Sankyo Europe GmbH

Sandeep Kiri

Sandeep Kiri, UCB Global Payer Value Strategy- Head of Health Economics and HTA Evidence, UCB

Remon Helmy

Remon Helmy, Senior Manager, Global Health Economics & Outcomes Research (HEOR), Alexion Pharmaceuticals

12:15 - 12:45

Solution Providers Presentation

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking

13:15 - 14:15

Pricing Market Access Strategies Case Studies

14:15 - 14:45

Assessing Patient centered approach to value-based approach

14:45 - 15:15

Closing remarks by the chairperson

15:15 - 15:15

End of Conference

15:15 - 15:15

CONFERENCE SPEAKERS

ADVISORS

Remon Helmy

Remon Helmy

Senior Manager, Global Health Economics & Outcomes Research (HEOR), Alexion Pharmaceuticals

SPEAKERS

Shahbaz Pervaiz

Shahbaz Pervaiz

Director of RWE Services, LynxCare, Inc.

Ivan Clement

Ivan Clement

Global Associate Director, RWE & Innovative Evidence in Neuroscience , Novartis

Veronika Schweighart

Veronika Schweighart

Co-Founder, Climedo

Sandeep Kiri

Sandeep Kiri

UCB Global Payer Value Strategy- Head of Health Economics and HTA Evidence, UCB

Michael Happich

Michael Happich

Sr Director HTA, International Markets, Eli Lilly and Company

Alexandre Templier

Alexandre Templier

President, Quinten Health

Christian Müller

Christian Müller

Head of Data Generation, Bayer

Alberto Brage

Alberto Brage

Global Key Account Manager, Savanamed

Helene Vioix

Helene Vioix

Director Global Evidence & Value Development Oncology, Merck KGaA

Davy Yeung

Davy Yeung

Managing Director and Vice President of Operations, Tailored Clinical Research Solutions

Remon Helmy

Remon Helmy

Senior Manager, Global Health Economics & Outcomes Research (HEOR), Alexion Pharmaceuticals

Meritxell Sabidó

Meritxell Sabidó

Director- Global Epidemiology Department, Neurology and Immunology, Merck Healthcare KgaA

Anila Dede

Anila Dede

Executive Director -Medical Affairs, RW Solutions, SyneosHealth

Oisin Butler

Oisin Butler

Integrated Evidence Generation Lead, Bayer Radiology

Dries Hens

Dries Hens

Chief Medical Officer, Co-founder , LynxCare

ENQUIRE NOW

SPONSORS

Savana
TCRS (Tailored Clinical Research Solutions)
Cegedim
Flatiron Health
Nested Knowledge
LynxCare
Quinten Health
Climedo
Syneos Health
Adelphi Real World
Numerus

PARTNERS

LOCATION

Venue

The Westin Grand Frankfurt, Germany

PAST EVENT GALLERY